SOLLUM TECHNOLOGIES PARTNERS WITH OPTIMAL TO ADVANCE AI GREENHOUSE CONTROL
MONTRÉAL and LONDON, June 10, 2025 /CNW/ - Sollum Technologies is pleased to announce a strategic partnership with Optimal, a leader in AI greenhouse control. This collaboration integrates Sollum's 100% dynamic LED lighting with Optimal's AI climate and irrigation control platform, enabling growers to precisely execute their desired growing strategy under rapidly changing weather conditions.
"Growers today use Optimal to create their desired climate conditions without spending hours adjusting settings," said Dave Hunter, CEO and Founder of Optimal. "With Optimal, growers spend less than 10 minutes per week on climate and irrigation control, yet achieve higher yield, quality, and energy efficiency. Lighting is one of the most powerful levers in a greenhouse. Integrating with Sollum's dynamic LEDs gives our AI the flexibility to adjust that lever in real time. It's a natural extension of our platform."
By integrating with Sollum's proprietary SUN as a Service® platform, Optimal's AI anticipates the impact of light and balances it with climate and irrigation in real time. Optimal's AI seamlessly updates settings in the grower's existing control computer. The result for growers is a fully automated system that precisely executes their growing strategy 24/7 across lighting, climate, and irrigation.
"Our dynamic lighting solution was built to adapt — and this partnership takes that adaptability to the next level," said François R.-Moisan, co-founder and CTO at Sollum Technologies. "By connecting with Optimal's decision-making engine, our platform becomes even more responsive to crop needs. Together, we're providing growers with a seamless and intelligent way to optimize production."
To learn more about Sollum's dynamic LED solution, please contact:
USA: Matthew Bonavita, Vice President of Sales (mobile: +1 (919) 413-0365)
Canada: Jon Adams, Vice President of Sales (mobile: +1 (905) 321-6855)
To learn more about Optimal Climate and Irrigation, please contact:
Dave Hunter, CEO and Founder (mobile: +447872956856)
About Sollum Technologies
Sollum Technologies designed the only 100% dynamic LED lighting solution that modulates the full spectrum of the Sun's natural light to illuminate closed environments such as greenhouses, research centers and laboratories. Sollum's award-winning, turnkey solution consists of internet of things, AI-powered light fixtures that are controlled by Sollum's proprietary SUN as a Service® cloud platform. Sollum's distinctive proposition is a fully scalable cleantech solution that evolves with business needs and multi-zone light management, with each zone benefiting from automatic dimming of an unlimited number of light recipes; this is why it provides unparalleled value in terms of energy savings and, additionally for greenhouse growers, increased productivity, and superior produce quality.
Founded in 2015, the company is headquartered in Montréal (Québec, Canada), where its design, development, and manufacturing activities are concentrated, and has representative offices in Leamington (Ontario, Canada) and Atlanta (Georgia, USA). For more information, visit sollum.tech.
About Optimal
Optimal develops AI–powered software that helps growers achieve higher yield, product quality, and production reliability under rapidly changing conditions. Optimal's team comes from leading AI institutions including Google DeepMind, Microsoft, and Airbus Defence and Space. Optimal has customers in Europe and North America. Learn more at https://optimal.ag.
SOURCE Sollum Technologies
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
10 hours ago
- Cision Canada
Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors
TORONTO, June 11, 2025 /CNW/ - Specific Biologics Inc., a biotechnology company advancing Dualase® genome editors for precise and programmable in vivo genome editing, today announced the appointment of Paul J. Hastings as Chair of its Board of Directors. Mr. Hastings is a distinguished leader in the biopharmaceutical industry and currently serves as Chief Executive Officer and Board Member of engineered cell therapy company Nkarta since 2018. He is also a current Director of EnGene, a non-viral gene therapy company, and recently served as the Chair of the Biotechnology Innovation Organization (BIO). Over his career, he has held numerous top leadership roles, including CEO of OncoMed, QLT, Axys Pharmaceuticals, and LXR Biotechnology, and President of Chiron BioPharmaceuticals. He has guided corporate strategy as Chair of Pacira Biosciences, Proteon Therapeutics and Proteolix, and as a Director of ViaCyte, Relypsa and ViaCell, and previously held leadership roles in global biotechnology companies as President of Genzyme Therapeutics Europe and Genzyme Global Therapeutics, as well as progressive executive roles at Hoffmann-La Roche. A committed mentor and patient advocate, he co-founded and chairs the board of Youth Rally Inc. and serves on the Board of the Termeer Foundation. "I am thrilled to welcome Paul to the Board," said Brent Stead, CEO of Specific Biologics. "His proven ability to lead and scale high-impact biotechnology companies with breakthrough technologies will be instrumental as we advance our Dualase® platform toward the clinic for patients in need. We are entering an exciting new phase of growth, and Paul's leadership of the Board will be invaluable." "I'm honored to join the Board of Specific Biologics at such a pivotal time," said Hastings. "The Dualase® technology has the potential to reshape how we approach treating some of the most challenging genetic diseases. I look forward to working with the leadership team and Board to support Specific's mission and drive meaningful impact for patients with limited therapeutic options." Specific Biologics also extends its sincere gratitude to Dr. Steven Kanner for his dedicated service on the Board and guidance during a critical phase of the company's development. "Steve played a key role in helping shape our early strategy and set the foundation for our current momentum," said Stead. About Specific Biologics Inc. Specific Biologics is a venture-backed biotechnology company developing Dualase®, an industry-leading genome editing platform for precise, efficient, and programmable in vivo genome editing, with an initial therapeutic focus on the precise collapse of pathogenic repeat expansions in neurodegenerative disease. Its unique two-site mechanism enables the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase® achieves best-in-class accurate editing efficiency with undetectable off-target effects as demonstrated in preclinical cell and animal models at diverse targets and indications.
Cision Canada
12 hours ago
- Cision Canada
ASUS Announces Key Milestone with Nebius and Showcases NVIDIA GB300 NVL72 System at GTC Paris 2025
Accelerating AI with scalable performance and next-gen infrastructure PARIS, June 11, 2025 /CNW/ -- ASUS today joined GTC Paris at VivaTech 2025 as a Gold Sponsor, highlighting its latest portfolio of AI infrastructure solutions and reinforcing its commitment to advancing the AI Factory vision with a full range of NVIDIA ® Blackwell Ultra solutions, delivering breakthrough performance from large-scale datacenter to personal desktop. ASUS is also excited to announce a transformative partnership milestone in its partnership with Nebius. Together, the two companies are enabling a new era of AI innovation built on NVIDIA's advanced platforms. Building on the success of the NVIDIA GB200 NVL72 platform deployment, ASUS and Nebius are now moving forward with strategic collaborations featuring the next-generation NVIDIA GB300 NVL72 platform. This ongoing initiative underscores ASUS's role as a key enabler in AI infrastructure, committed to delivering scalable, high-performance solutions that help enterprises accelerate AI adoption and innovation. Andrey Korolenko, Chief Product and Infrastructure Officer at Nebius said: "We have collaborated with ASUS for many years and appreciate its impressive capability to deliver swift and efficient solutions. ASUS not only delivers consistently against our exacting technical requirements, but also demonstrates deep professional expertise in building AI infrastructure. The company's forward-thinking approach and technical excellence have been a key enabler for our projects, and we look forward to working together to deliver the next generations of AI infrastructure." AI servers: Building NVIDIA AI Factories for enterprise Leading the charge in AI advancement, ASUS is driving scalable, agentic AI through increased token generation. At GTC Paris, ASUS will unveil its latest AI Factory infrastructure solutions built on NVIDIA RTX PRO Servers as well as the NVIDIA Grace Blackwell Ultra systems. The ASUS AI POD, built with the NVIDIA GB300 NVL72 system, delivers exceptional performance for complex AI inference tasks, making it ideal for advanced AI applications. Meanwhile, ASUS XA NB3I-E12, featuring the NVIDIA HGX B300 system, pushes the boundaries of AI computing with higher FLOPS and a massive 2.3TB of HBM3e memory — accelerating training and inference for large-scale models. To further address the growing demands of high-performance AI and HPC environments, ASUS introduced the new ESC8000A-E13P. This 4U NVIDIA MGX server supports up to eight NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs, NVIDIA BlueField-3 DPUs, and NVIDIA ConnectX-8 SuperNICs with built-in PCIe® 6.0 switches, offering seamless integration, performance optimization, and scalability for modern data centers and agile IT deployments AI Inferencing: Enabling intelligent services at scale ASUS also unveiled powerful AI inference solutions, introducing a new lineup of workstations and a compact-sized supercomputer engineered to tackle today's most demanding workloads. Leading the range is the ExpertCenter Pro ET900N G3, the first system powered by the NVIDIA GB300 Grace Blackwell Ultra Superchip, with up to 784GB of large coherent memory. Another is the groundbreaking ASUS Ascent GX10, a compact AI supercomputer powered by the NVIDIA GB10 Grace Blackwell Superchip, that delivers 1,000 AI TOPS performance for demanding workloads. Equipped with a NVIDIA Blackwell GPU, 20-core Arm CPU, and 128GB of memory, it supports AI models up to 200-billion parameters, placing petaflop-scale inferencing capabilities on developers' desks. Designed from the ground up for AI, both products deliver exceptional performance for large-scale training and inference on a desktop. Combined with the NVIDIA AI s oftware s tack, it is purpose-built for teams that demand the best in AI development. ASUS: Proven expertise in AI infrastructure With server expertise dating back to 1995, ASUS delivers reliable, end-to-end infrastructure solutions —ranging from individual components to fully integrated systems — backed by world-class R&D and global manufacturing capabilities. Driven by the Ubiquitous AI, Incredible Possibilities vision, ASUS supports clients in accelerating their advancement in the global AI race. Through flexible customization, deep technical expertise, and a proven track record in deployment, ASUS empowers enterprises to scale AI initiatives with confidence and efficiency.
Cision Canada
a day ago
- Cision Canada
Spiderwort Biotechnologies Inc. Receives Health Canada Investigational Testing Authorization for Next-Generation Dermal Filler
® represents the next-generation in medical aesthetics leveraging Spiderwort Biotechnologies regenerative cellulose-based technology platform OTTAWA, ON, June 10, 2025 /CNW/ - Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, today announced it has received Investigational Testing Authorization (ITA) from Health Canada for CelluJuve ®, its next-generation cellulose-based dermal filler currently under development. The ITA enables Spiderwort Biotechnologies Inc. to initiate a human clinical trial in Canada to evaluate the safety and performance of CelluJuve ® for tissue augmentation and rejuvenation. The planned clinical trials will evaluate the interaction between CelluJuve® and human tissues. This authorization follows the company's successful completion of ISO 10993 biocompatibility testing and human skin safety testing for CelluJuve ®. "Receiving the Investigational Testing Authorization from Health Canada is a critical inflection point in our mission to transform the landscape of regenerative medicine in multiple categories," said Dr. Charles M. Cuerrier, CEO of Spiderwort Biotechnologies Inc."This achievement validates our rigorous development approach and accelerates our path toward bringing CelluJuve ® to patients and clinicians who are seeking innovative alternatives in dermal fillers. We're excited to begin the clinical evaluation phase and demonstrate the potential benefits of our cellulose-based technology Aerocel™ in medical aesthetics and beyond." "As a board certified dermatologist with extensive experience in facial aesthetics, I am encouraged by CelluJuve®'s innovative approach to tissue augmentation." Dr. Joely Kaufman, MD, FAAD, member of Spiderwort's Clinical Advisory Board, "The preliminary data suggests that this cellulose-based technology could potentially offer an alternative method to address the signs of facial aging. I look forward to seeing the clinical results of this promising biomaterial." CelluJuve ® is under development to provide medical professionals with a cellulose-based alternative to current dermal fillers. The product is designed to work with the body to create a natural look and feel by providing a framework for collagen deposition, with the initial target for Spiderwort Biotechnologies Inc.'s research being nasolabial fold remediation. The company's state-of-the-art ISO 5 cleanroom facility, announced earlier this year, will support the production of medical-grade CelluJuve ® for the upcoming trials, ensuring all materials meet the quality standards required for human use. "CelluJuve® is a testament to where bold science can lead," said Dr. Andrew Pelling, Chief Science Officer at Spiderwort Biotechnologies Inc."We're demonstrating how plant-derived biomaterials can become a powerful foundation to address a variety of medical needs. These recent and critical regulatory advancements in our product portfolio reveal how nature inspired innovation can unlock entirely new frontiers in rejuvenating and regenerating human tissues." CelluJuve ® is a device under development. While it has received Investigational Testing Authorization from Health Canada for clinical trials, it is not yet approved by Health Canada or the U.S. Food and Drug Administration (FDA) for commercial use, and it is not available for sale. The safety and effectiveness of CelluJuve ® in humans has not been fully established and will be evaluated in upcoming clinical trials. For more information about Spiderwort Biotechnologies and CelluJuve ®, please visit About Spiderwort Biotechnologies Inc. Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort's biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at
